BIBB

Image Source: Paul Sableman There has been a notable rise in the intent of the old guard in the pharmaceutical realm to divest some non-core assets via spin-offs into new, standalone companies. We believe we are on the cusp of a trend of simplification which we feel will aid in growing the top line sustainably, something that has become notoriously difficult for big pharma. By Alexander J. Poulos Eli Lilly Eli Lilly (LLY) mentioned on its recent quarterly conference call the need to explore strategic alternatives for its Elanco animal health unit, which is suffering from sales deceleration due to a decrease in end-user demand for its products. Elanco posted sales of $2.29 billion during the first three quarters of … Read more